Sort   by:  
 Page size 
ProteomicsTIMEPOINT, a phase 1 study of MTL-CEBPA in combination with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumours.
Many cancer patients don’t benefit from currently-approved immune checkpoint inhibitors (ICI), suggesting that additional immunomodulation of the immunosuppressive tumour microenvironment (TME) is required. MTL-CEBPA specifically upregulates expression of master myeloid transcription factor, CEBPA, ...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD060726 | Pride
Human Cancer Plasma proteome Immunomodulatory 
UnknownThe New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs.
Not available
S-EPMC10874267 | biostudies-literature
UnknownThe New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs.
Not available
S-EPMC10197800 | biostudies-literature
UnknownSARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Not available
S-EPMC9762734 | biostudies-literature
UnknownPrehospital use of magnesium sulfate as neuroprotection in acute stroke.
Not available
S-EPMC4920545 | biostudies-literature
UnknownMuscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials.
Not available
S-EPMC6166612 | biostudies-literature
UnknownMutation and association analysis of GEN1 in breast cancer susceptibility.
Not available
S-EPMC3632835 | biostudies-literature
Unknown2023 Canadian Surgery Forum: Sept. 20-23, 2023.
Not available
S-EPMC10718225 | biostudies-literature
UnknownDistinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.
Not available
S-EPMC9043502 | biostudies-literature
UnknownGermline mutations in RAD51D confer susceptibility to ovarian cancer.
Not available
S-EPMC4845885 | biostudies-literature
Sort   by:  
 Page size